---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-007845"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:20:33.179913+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# RxSight Q1 revenue up 157% to $8.9M; raises 2022 revenue guidance

## Summary
- Revenue $8.9M (+157% YoY); LDD sales 40 units (+208%), installed base 246 (+134%).
- Net loss $17.6M ($0.64/share); adjusted net loss $14.9M ($0.54/share).
- 2022 revenue guidance raised to $41.5-45.5M from $40-44M, implying 84-101% annual growth.
- Amended Oxford Finance loan: extends draw periods for remaining $20M, interest-only period to 2025.
- Procedure volumes: 4,166 LALs sold (+166% YoY).

## SEC filing metadata
- accession: 0000950170-22-007845
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000095017022007845/0000950170-22-007845-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000095017022007845/rxst-20220505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-007845
- JSON: https://secwatch.observer/filing/0000950170-22-007845.json
- Plain text: https://secwatch.observer/filing/0000950170-22-007845.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.